FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1646509809> ?p ?o ?g. }

• W1646509809 endingPage "1048" @default.
• W1646509809 startingPage "1039" @default.
• W1646509809 abstract "Osteopontin (OPN) mediates metastasis and invasion of hepatocellular carcinoma (HCC). Epigallocatechin-3-gallate (EGCG), found in green tea, suppresses HCC tumor growth in vitro. We sought to investigate the role of EGCG in modulating OPN in cell lines of metastatic HCC.Experimental HCC cell lines included HepG2 and MHCC-97H HCC cells, which express high levels of OPN, and the Hep3B cells, which express lesser levels of OPN. Cells were treated with EGCG (0.02-20 μg/mL) before measurement of OPN with enzyme-linked immunosorbent assay and reverse transcriptase-polymerase chain reaction. Scratch assay measured cell migration. Binding of the OPN promoter to RNA pol II was evaluated by the use of Chromatin-IP assay after EGCG treatment. Transcriptional regulation of OPN was investigated with luciferase reporter plasmids containing various deletion fragments of the human OPN promoter. Measurement of the half-life of OPN mRNA was conducted using actinomycin D.Treatment of MHCC-97H and HepG2 cells with 2 μg/mL and 20 μg/mL EGCG caused a ∼6-fold and ∼90-fold decrease in secreted protein levels of OPN (All P < .001). OPN mRNA was decreased with EGCG concentrations of 0.2-20 μg/ml (All P < .001). The 3-(4, 5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (ie, MTT) assay revealed that differences in OPN expression were not due to viability of the HCC cell lines. Promoter assay and chromatin immunoprecipitation analysis revealed no effect of EGCG on the transcriptional regulation of OPN. Posttranscriptionally, EGCG decreased the half-life of OPN mRNA from 16.8 hours (95% confidence interval 9.0-125.1) to 2.5 hours (95% confidence interval 2.1-3.2) (P < .001). Migration was decreased in EGCG treated cells at 24 hours (8.0 ± 2.4% vs 21.2 ± 10.8%, P < .01) and at 48 hours (13.2 ± 3.6% vs 53.5 ± 19.8%, P < .001).We provide evidence that EGCG decreases OPN mRNA and secreted OPN protein levels by decreasing the half-life of OPN mRNA in MHCC-97H cells. The translatability of EGCG for patients with HCC is promising, because EGCG is an inexpensive, easily accessible chemical with an extensive history of safety." @default.
• W1646509809 created "2016-06-24" @default.
• W1646509809 creator A5012915140 @default.
• W1646509809 creator A5015506429 @default.
• W1646509809 creator A5016777555 @default.
• W1646509809 creator A5021386039 @default.
• W1646509809 creator A5024436230 @default.
• W1646509809 creator A5052594345 @default.
• W1646509809 creator A5068001843 @default.
• W1646509809 creator A5077843932 @default.
• W1646509809 creator A5083956940 @default.
• W1646509809 date "2015-10-01" @default.
• W1646509809 modified "2023-10-13" @default.
• W1646509809 title "Green tea component epigallocatechin-3-gallate decreases expression of osteopontin via a decrease in mRNA half-life in cell lines of metastatic hepatocellular carcinoma" @default.
• W1646509809 cites W1549674551 @default.
• W1646509809 cites W1574542346 @default.
• W1646509809 cites W1972868257 @default.
• W1646509809 cites W1984699774 @default.
• W1646509809 cites W1990777354 @default.
• W1646509809 cites W1997044508 @default.
• W1646509809 cites W2003153226 @default.
• W1646509809 cites W2004379650 @default.
• W1646509809 cites W2006237497 @default.
• W1646509809 cites W2007590062 @default.
• W1646509809 cites W2010776776 @default.
• W1646509809 cites W2020664220 @default.
• W1646509809 cites W2020730293 @default.
• W1646509809 cites W2026229149 @default.
• W1646509809 cites W2030697697 @default.
• W1646509809 cites W2030698160 @default.
• W1646509809 cites W2035810928 @default.
• W1646509809 cites W2055292119 @default.
• W1646509809 cites W2082419651 @default.
• W1646509809 cites W2083113175 @default.
• W1646509809 cites W2086887428 @default.
• W1646509809 cites W2087027618 @default.
• W1646509809 cites W2092057906 @default.
• W1646509809 cites W2106787323 @default.
• W1646509809 cites W2133816851 @default.
• W1646509809 cites W2139240475 @default.
• W1646509809 cites W2142302251 @default.
• W1646509809 cites W2152835156 @default.
• W1646509809 doi "https://doi.org/10.1016/j.surg.2015.06.011" @default.
• W1646509809 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5105906" @default.
• W1646509809 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26189955" @default.
• W1646509809 hasPublicationYear "2015" @default.
• W1646509809 type Work @default.
• W1646509809 sameAs 1646509809 @default.
• W1646509809 citedByCount "15" @default.
• W1646509809 countsByYear W16465098092016 @default.
• W1646509809 countsByYear W16465098092017 @default.
• W1646509809 countsByYear W16465098092018 @default.
• W1646509809 countsByYear W16465098092019 @default.
• W1646509809 countsByYear W16465098092020 @default.
• W1646509809 countsByYear W16465098092021 @default.
• W1646509809 countsByYear W16465098092023 @default.
• W1646509809 crossrefType "journal-article" @default.
• W1646509809 hasAuthorship W1646509809A5012915140 @default.
• W1646509809 hasAuthorship W1646509809A5015506429 @default.
• W1646509809 hasAuthorship W1646509809A5016777555 @default.
• W1646509809 hasAuthorship W1646509809A5021386039 @default.
• W1646509809 hasAuthorship W1646509809A5024436230 @default.
• W1646509809 hasAuthorship W1646509809A5052594345 @default.
• W1646509809 hasAuthorship W1646509809A5068001843 @default.
• W1646509809 hasAuthorship W1646509809A5077843932 @default.
• W1646509809 hasAuthorship W1646509809A5083956940 @default.
• W1646509809 hasBestOaLocation W16465098092 @default.
• W1646509809 hasConcept C101762097 @default.
• W1646509809 hasConcept C104317684 @default.
• W1646509809 hasConcept C105580179 @default.
• W1646509809 hasConcept C134320426 @default.
• W1646509809 hasConcept C150194340 @default.
• W1646509809 hasConcept C153911025 @default.
• W1646509809 hasConcept C203014093 @default.
• W1646509809 hasConcept C2780804394 @default.
• W1646509809 hasConcept C502942594 @default.
• W1646509809 hasConcept C53227056 @default.
• W1646509809 hasConcept C54355233 @default.
• W1646509809 hasConcept C55493867 @default.
• W1646509809 hasConcept C71924100 @default.
• W1646509809 hasConcept C81885089 @default.
• W1646509809 hasConcept C86803240 @default.
• W1646509809 hasConceptScore W1646509809C101762097 @default.
• W1646509809 hasConceptScore W1646509809C104317684 @default.
• W1646509809 hasConceptScore W1646509809C105580179 @default.
• W1646509809 hasConceptScore W1646509809C134320426 @default.
• W1646509809 hasConceptScore W1646509809C150194340 @default.
• W1646509809 hasConceptScore W1646509809C153911025 @default.
• W1646509809 hasConceptScore W1646509809C203014093 @default.
• W1646509809 hasConceptScore W1646509809C2780804394 @default.
• W1646509809 hasConceptScore W1646509809C502942594 @default.
• W1646509809 hasConceptScore W1646509809C53227056 @default.
• W1646509809 hasConceptScore W1646509809C54355233 @default.
• W1646509809 hasConceptScore W1646509809C55493867 @default.
• W1646509809 hasConceptScore W1646509809C71924100 @default.
• W1646509809 hasConceptScore W1646509809C81885089 @default.
• W1646509809 hasConceptScore W1646509809C86803240 @default.
• W1646509809 hasIssue "4" @default.

• next